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To the Editor:
A 52-year-old woman was hospitalized for worsening
chronic cluster headache refractory to all guideline-based
medical and invasive treatments. Based on class IV evi-
dence [1] she had regularly taken high-dose gamma-
hydroxybutyrate GHB = sodium oxybate (Xyrem®;
UCB-Pharma AG, Bulle, Switzerland) 4.5 g twice-nightly
at 2300 and 0300 hours for the last 6 years. This was the
only drug that markedly improved her nocturnal headache
episodes and insomnia. As an additional therapeutic effort,
topiramate (Topamax®; Janssen-Cilag AG, Baar, Switzer-
land) was added to the therapeutic regime, with the patient
taking a single dose of topiramate 25 mg at 1800 hours,
followed by the usual two daily doses of GHB. The next
morning the patient had developed confusion, followed by
intermittent myoclonic jerks, miosis, and a rapid onset of
coma [Glasgow Coma Scale (GCS) score was 3 at 0800
hours]. Pulse, blood pressure, respiratory rate, pulse oxi-
metry, electrocardiogram, and laboratory values, including
electrolytes and blood glucose, were unremarkable. The
plasma GHB concentration, determined by gas chromatog-
raphy–mass spectrometry (GC-MS) of a blood sample
collected at 0800 hours, was 259 mg/L. One hour later
electroencephalography (EEG) showed intermittent bifron-
tal theta activity, a pattern described during sedation with
GHB [2]. At 1300 hours the patient awoke from coma and
rapidly recovered within a few hours. Topiramate was
stopped, but GHB was continued as before. Two days later
the plasma GHB concentration was 91 mg/L based on GC-
MS analysis of a blood sample collected at 0800 hours.
In this patient, who was given topiramate concomitant
with GHB, the GHB concentration 5 h after the second daily
dose of GHB was 2.8-fold higher than without topiramate,
and 1.8-fold higher than the peak concentration of 142 mg/L
that would be expected 0.5–2 h after the daily second dose
according to Xyrem®’s product information. The patient
had taken topiramate without concomitant GHB in the past
without problems. Based on the rapid onset but short dura-
tion of the otherwise unexplained coma and the EEG find-
ings, we suggest that the coma was drug induced due to a
pharmacokinetic interaction between GHB and topiramate.
GHB has a short half-life of about 30 min [3], and metab-
olism via GHB-dehydrogenase is its main route of elimina-
tion [4]. In vitro studies have demonstrated that GHB-
dehydrogenase is inhibited by the antiepileptic drugs val-
proate and ethosuximide [4], but according to Xyrem®’s
product information no interaction studies with antiepilep-
tics have been performed in humans. Alternatively, changes
in the bioavailability of GHB or other unknown mechanisms
of interaction are theoretically possible. In addition, topir-
amate increases GABA activity at its neuroreceptors, and an
additional pharmacodynamic interaction must therefore also
be considered.
In light of the increasing therapeutic as well as illicit use
of GHB, as well as of newer antiepileptic drugs, possible
interactions should be evaluated in formal pharmacokinetic
studies. In the mean time, we suggest using such combina-
tions only with great care.
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